SEC Company Response from Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Jul 24, 2023
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: July 24, 2023 · CIK: 0001512762 · Accession: 0001193125-23-192311
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273179
Letter
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
July 24, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: Coherus BioSciences, Inc.
Registration Statement on Form S-4
(File No. 333-273179)
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Coherus BioSciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-4 initially filed on July 7, 2023 and amended on July 24, 2023 (the “Registration Statement”). The Company respectfully requests that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on July 26, 2023, or as soon thereafter as practicable. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Latham & Watkins LLP, by calling Benjamin A. Potter at (650) 470-4809.
Very truly yours,
Coherus BioSciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 July 24, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Coherus BioSciences, Inc. Registration Statement on Form S-4 (File No. 333-273179) Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Coherus BioSciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-4 initially filed on July 7, 2023 and amended on July 24, 2023 (the “Registration Statement”). The Company respectfully requests that the Registration Statement become effective as of 4:00 p.m., Eastern Time, on July 26, 2023, or as soon thereafter as practicable. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Latham & Watkins LLP, by calling Benjamin A. Potter at (650) 470-4809. Very truly yours, Coherus BioSciences, Inc. By: /s/ McDavid Stilwell Name: McDavid Stilwell Title: Chief Financial Officer cc: Dennis M. Lanfear, Coherus BioSciences, Inc. Bryan McMichael, Coherus BioSciences, Inc. Benjamin A. Potter, Latham & Watkins LLP Phillip S. Stoup, Latham & Watkins LLP